SCHEMBL6514156

SCHEMBL6514156

COc1ccc(C(=O)NCCn2c(=O)c3c(C)[nH]nc3c3ccccc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.50
KDR P35968 1/20 0.50
AURKB Q96GD4 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
ALDH1A1 P00352 2/20 0.49
POLB P06746 4/20 0.48
MAPT P10636 5/20 0.47
HDAC1 Q13547 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
TP53 P04637 1/20 0.44
PLD2 O14939 1/20 0.44
PLD1 Q13393 1/20 0.44
USP2 O75604 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6513032 0.89 CHEK1 (0.53) AURKAKDRAURKBSMN1; SMN2ALDH1A1
SCHEMBL6514632 0.84 TRPV1 (0.47) AURKAKDRAURKBALDH1A1POLB
SCHEMBL6523103 0.83 CHEK1 (0.55) AURKAKDRAURKBSMN1; SMN2ALDH1A1
SCHEMBL6517752 0.83 AURKA (0.50) AURKAKDRAURKBMEN1KMT2A
SCHEMBL6513140 0.83 AURKA (0.49) AURKAKDRAURKBMEN1KMT2A
SCHEMBL6521705 0.82 AURKA (0.51) AURKAKDRAURKBNPC1SMN1; SMN2
SCHEMBL6513075 0.82 AURKA (0.48) AURKAKDRAURKBKMT2AALDH1A1
SCHEMBL6515113 0.82 AURKA (0.48) AURKAKDRAURKBSMN1; SMN2ALDH1A1
SCHEMBL6514908 0.81 AURKA (0.47) AURKAKDRAURKBALDH1A1POLB
SCHEMBL6515420 0.80 AURKA (0.47) AURKAKDRAURKBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 AURKA 78/4885KDR 1094/4885AURKB 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.